Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Withdrawn × NETWORK × olaparib × Clear all

Phase

Status

Completed 3 Recruiting 2 Withdrawn 1

Sponsor Class

OTHER 6 INDUSTRY 4 NIH 3 NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Triple Negative Breast Neoplasms 1

Interventions

Cisplatin 13 Radiotherapy 12 Oxaliplatin 8 Fluorouracil 7 Gemcitabine 6 Drug Therapy 6 Leucovorin 5 Doxorubicin 5 Cyclophosphamide 5 Carboplatin 5 Capecitabine 5 durvalumab 4 Etoposide 4 Cytarabine 4 Chemotherapy, Adjuvant 4 Biological Therapy 4 bicalutamide 3 Rituximab 3 Radiotherapy, Intensity-Modulated 3 Polymerase Chain Reaction 3 Platinum 3 Peripheral Blood Stem Cell Transplantation 3 Paclitaxel 3 Methylprednisolone 3 Gene Expression Profiling 3 Bortezomib 3 1,2-diaminocyclohexaneplatinum II citrate 3 lenvatinib 2 imetelstat 2 fludarabine phosphate 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05209529 2024-02-23

Chemo-free BRCA-targeted Neoadjuvant Strategy

European Organisation for Research and Treatment of Cancer - EORTC

Phase 2 Withdrawn

Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡